Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia

References

• Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569–572.
   PubMed Web of Science ®Google Scholar
• Hoekstra D, Maier O, van der Wouden JM, Slimane TA, van ISC. Membrane dynamics and cell polarity: the role of sphingolipids. J Lipid Res 2003;44:869–877.
   Google Scholar
• Piccinini M, Scandroglio F, Prioni S, Buccinna B, Loberto N, Aureli M, . Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders. Mol Neurobiol 2010;41:314–340.
   PubMed Web of Science ®Google Scholar
• Yu ZF, Nikolova-Karakashian M, Zhou D, Cheng G, Schuchman EH, Mattson MP. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci 2000;15:85–97.
   PubMed Web of Science ®Google Scholar
• Singh IN, Hall ED. Multifaceted roles of sphingosine-1-phosphate: how does this bioactive sphingolipid fit with acute neurological injury? J Neurosci Res 2008;86: 1419–1433.
   PubMed Web of Science ®Google Scholar
• Novgorodov SA, Gudz TI. Ceramide and mitochondria in ischemia/reperfusion. J Cardiovasc Pharmacol 2009;53: 198–208.
   PubMed Web of Science ®Google Scholar
• Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010;1801:878–886.
   Google Scholar
• Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982;4:115–135.
   PubMed Web of Science ®Google Scholar
• Kramer PA, Chapron DJ, Benson J, Mercik SA. Tetracycline absorption in elderly patients with achlorhydria. Clin Pharmacol Ther 1978;23:467–472.
   PubMed Web of Science ®Google Scholar
• Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297–321.
   PubMedGoogle Scholar
• Klein NC, Cunha BA. Tetracyclines. Med Clin North Am 1995;79:789–801.
   PubMed Web of Science ®Google Scholar
• Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496–13500.
   PubMed Web of Science ®Google Scholar
• Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002;52:54–61.
   PubMed Web of Science ®Google Scholar
• Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009;196:168–179.
   PubMed Web of Science ®Google Scholar
• Jana A, Hogan EL, Pahan K. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 2009;278:5–15.
   PubMed Web of Science ®Google Scholar
• Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, . Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006;1758: 1864–1884.
   PubMedGoogle Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139–150.
   PubMed Web of Science ®Google Scholar
• Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9:162–176.
   PubMed Web of Science ®Google Scholar
• Posse de Chaves EI. Sphingolipids in apoptosis, survival and regeneration in the nervous system. Biochim Biophys Acta 2006;1758:1995–2015.
   PubMed Web of Science ®Google Scholar
• Canals D, Perry DM, Jenkins RW, Hannun YA. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 2011;163:694–712.
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002;277:25847–25850.
   PubMed Web of Science ®Google Scholar
• Wu BX, Clarke CJ, Hannun YA. Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. Neuromolecular Med 2010;12:320–330.
   PubMed Web of Science ®Google Scholar
• Zeidan YH, Hannun YA. The acid sphingomyelinase/ ceramide pathway: biomedical significance and mechanisms of regulation. Curr Mol Med 2010;10:454–466.
   PubMed Web of Science ®Google Scholar
• Stiban J, Tidhar R, Futerman AH. Ceramide synthases: roles in cell physiology and signaling. Adv Exp Med Biol 2010;688:60–71.
   Google Scholar
• Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, . Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:2070–2075.
   PubMed Web of Science ®Google Scholar
• Soderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 1992;59:1646–1653.
   PubMed Web of Science ®Google Scholar
• Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuramochi T, Frosch MP, . Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J Biol Chem 2000;275:27901–27908.
   PubMed Web of Science ®Google Scholar
• Yang DI, Yeh CH, Chen S, Xu J, Hsu CY. Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 2004;17: 99–107.
   PubMed Web of Science ®Google Scholar
• Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, . Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004;164:123–131.
   PubMed Web of Science ®Google Scholar
• Chen S, Lee JM, Zeng C, Chen H, Hsu CY, Xu J. Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J Neurochem 2006;97:631–640.
   PubMed Web of Science ®Google Scholar
• Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med 2005;38:938–949.
   PubMed Web of Science ®Google Scholar
• Jana A, Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem 2004;279:51451–51459.
   PubMed Web of Science ®Google Scholar
• Ayasolla K, Khan M, Singh AK, Singh I. Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med 2004;37:325–338.
   PubMed Web of Science ®Google Scholar
• Han X, D MH, McKeel DW Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002;82:809–818.
   PubMed Web of Science ®Google Scholar
• Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 2004;32:144–146.
   PubMed Web of Science ®Google Scholar
• Kubota M, Kitahara S, Shimasaki H, Ueta N. Accumulation of ceramide in ischemic human brain of an acute case of cerebral occlusion. Jpn J Exp Med 1989;59:59–64.
   PubMedGoogle Scholar
• Kubota M, Narita K, Nakagomi T, Tamura A, Shimasaki H, Ueta N, Yoshida S. Sphingomyelin changes in rat cerebral cortex during focal ischemia. Neurol Res 1996;18:337–341.
   PubMed Web of Science ®Google Scholar
• Nakane M, Kubota M, Nakagomi T, Tamura A, Hisaki H, Shimasaki H, Ueta N. Lethal forebrain ischemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus. Neurosci Lett 2000;296:89–92.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ginis I, Nishioka R, Klimanis D, Barone FC, White RF, . Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning. J Cereb Blood Flow Metab 2004;24:623–627.
   PubMed Web of Science ®Google Scholar
• Ohtani R, Tomimoto H, Kondo T, Wakita H, Akiguchi I, Shibasaki H, Okazaki T. Upregulation of ceramide and its regulating mechanism in a rat model of chronic cerebral ischemia. Brain Res 2004;1023:31–40.
   PubMed Web of Science ®Google Scholar
• Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002;52:448–457.
   PubMed Web of Science ®Google Scholar
• Bras J, Singleton A, Cookson MR, Hardy J. Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J 2008;275: 5767–5773.
   PubMed Web of Science ®Google Scholar
• Agudo-Lopez A, Miguel BG, Fernandez I, Martinez AM. Role of protein kinase C and mitochondrial permeability transition pore in the neuroprotective effect of ceramide in ischemia-induced cell death. FEBS Lett 2011;585:99–103.
   PubMed Web of Science ®Google Scholar
• Furuya K, Ginis I, Takeda H, Chen Y, Hallenbeck JM. Cell permeable exogenous ceramide reduces infarct size in spontaneously hypertensive rats supporting in vitro studies that have implicated ceramide in induction of tolerance to ischemia. J Cereb Blood Flow Metab 2001;21:226–232.
   PubMed Web of Science ®Google Scholar
• Galadari S, Kishikawa K, Kamibayashi C, Mumby MC, Hannun YA. Purification and characterization of ceramide-activated protein phosphatases. Biochemistry 1998;37:11232–11238.
   PubMed Web of Science ®Google Scholar
• Kitatani K, Idkowiak-Baldys J, Hannun YA. Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641. J Biol Chem 2007;282: 20647–20656.
   PubMed Web of Science ®Google Scholar
• Bourbon NA, Yun J, Berkey D, Wang Y, Kester M. Inhibitory actions of ceramide upon PKC-epsilon/ERK interactions. Am J Physiol Cell Physiol 2001;280:C1403–C1411.
   PubMed Web of Science ®Google Scholar
• Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, . Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007;282:12450–12457.
   PubMed Web of Science ®Google Scholar
• Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 1998;17:3277–3285.
   PubMed Web of Science ®Google Scholar
• Gill JS, Windebank AJ. Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis. Neurobiol Dis 2000;7:448–461.
   PubMed Web of Science ®Google Scholar
• Mullen TD, Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem 2011;12:340–363.
   Web of Science ®Google Scholar
• Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 2006;1758: 2027–2036.
   PubMed Web of Science ®Google Scholar
• Arboleda G, Morales LC, Benitez B, Arboleda H. Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. Brain Res Rev 2009;59:333–346.
   PubMedGoogle Scholar
• Ardail D, Popa I, Alcantara K, Pons A, Zanetta JP, Louisot P, . Occurrence of ceramides and neutral glycolipids with unusual long-chain base composition in purified rat liver mitochondria. FEBS Lett 2001;488:160–164.
   PubMed Web of Science ®Google Scholar
• Deng X, Yin X, Allan R, Lu DD, Maurer CW, Haimovitz-Friedman A, . Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science 2008;322:110–115.
   PubMed Web of Science ®Google Scholar
• Birbes H, El Bawab S, Hannun YA, Obeid LM. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis. FASEB J 2001;15:2669–2679.
   PubMed Web of Science ®Google Scholar
• Birbes H, Luberto C, Hsu YT, El Bawab S, Hannun YA, Obeid LM. A mitochondrial pool of sphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochem J 2005;386:445–451.
   PubMed Web of Science ®Google Scholar
• Stiban J, Caputo L, Colombini M. Ceramide synthesis in the endoplasmic reticulum can permeabilize mitochondria to proapoptotic proteins. J Lipid Res 2008;49:625–634.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 1997;272:11369–11377.
   PubMed Web of Science ®Google Scholar
• Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 1997;272:21388–21395.
   PubMed Web of Science ®Google Scholar
• Charruyer A, Grazide S, Bezombes C, Muller S, Laurent G, Jaffrezou JP. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem 2005;280: 19196–19204.
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Gulbins E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene 2006;25:5612–5625.
   PubMedGoogle Scholar
• Scheel-Toellner D, Wang K, Assi LK, Webb PR, Craddock RM, Salmon M, Lord JM. Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. Biochem Soc Trans 2004;32:679–681.
   PubMed Web of Science ®Google Scholar
• Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, . Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 2006;23:178–189.
   PubMed Web of Science ®Google Scholar
• Hsu MJ, Sheu JR, Lin CH, Shen MY, Hsu CY. Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration. Biochim Biophys Acta 2010;1800:290–296.
   PubMed Web of Science ®Google Scholar
• van Gurp M, Festjens N, van Loo G, Saelens X, Vandenabeele P. Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun 2003;304:487–497.
   PubMed Web of Science ®Google Scholar
• Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet 2009;43:95–118.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626–629.
   PubMed Web of Science ®Google Scholar
• Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999;66:1–15.
   PubMedGoogle Scholar
• Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011;21:92–101.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Matsumoto M, Tsujimoto Y, Ohtsuki T, Kuwabara K, Matsushita K, . Amelioration of hippocampal neuronal damage after global ischemia by neuronal overexpression of BCL-2 in transgenic mice. Stroke 1998;29: 2616–2621.
   PubMed Web of Science ®Google Scholar
• Liu D, Lu C, Wan R, Auyeung WW, Mattson MP. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J Cereb Blood Flow Metab 2002;22:431–443.
   PubMed Web of Science ®Google Scholar
• Rami A, Bechmann I, Stehle JH. Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog Neurobiol 2008;85:273–296.
   PubMed Web of Science ®Google Scholar
• Good ML, Hussey DL. Minocycline: stain devil? Br J Dermatol 2003;149:237–239.
   PubMed Web of Science ®Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258–265.
   PubMed Web of Science ®Google Scholar
• Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res 1998;12:5–11.
   PubMedGoogle Scholar
• Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30:1569–1575.
   PubMed Web of Science ®Google Scholar
• Colaizzi JL, Klink PR. pH-Partition behavior of tetracyclines. J Pharm Sci 1969;58:1184–1189.
   PubMed Web of Science ®Google Scholar
• Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005;94:819–827.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, . Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100: 10483–10487.
   PubMed Web of Science ®Google Scholar
• Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010;299:C539–C548.
   PubMed Web of Science ®Google Scholar
• Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769–15774.
   PubMed Web of Science ®Google Scholar
• Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010;67:1442–1448.
   PubMedGoogle Scholar
• Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 2006;53:233–240.
   PubMed Web of Science ®Google Scholar
• Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci 2007;27: 3057–3063.
   PubMed Web of Science ®Google Scholar
• Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis 2010;21: 527–542.
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Park CH, . Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007;32:2393–2404.
   PubMed Web of Science ®Google Scholar
• Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience 2008;154:1458–1466.
   PubMed Web of Science ®Google Scholar
• Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med 2007;48:1822–1828.
   PubMed Web of Science ®Google Scholar
• Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, . Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004;4:7.
   PubMed Web of Science ®Google Scholar
• Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, . Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669–14674.
   PubMed Web of Science ®Google Scholar
• Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797–801.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067–1070.
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, . Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74–78.
   PubMed Web of Science ®Google Scholar
• Soeda S, Tsuji Y, Ochiai T, Mishima K, Iwasaki K, Fujiwara M, . Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochem Int 2004;45:619–626.
   PubMed Web of Science ®Google Scholar
• Yu J, Novgorodov SA, Chudakova D, Zhu H, Bielawska A, Bielawski J, . JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J Biol Chem 2007;282:25940–25949.
   PubMed Web of Science ®Google Scholar
• Filipovic R, Zecevic N. Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia. Exp Neurol 2008;211:41–51.
   PubMed Web of Science ®Google Scholar
• Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, . Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci 2009;10:126.
   PubMed Web of Science ®Google Scholar
• Kernt M, Hirneiss C, Neubauer AS, Kampik A. Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP). Br J Ophthalmol 2010;94:940–946.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh K, Habibi-asl B, Farajnia S, Roshangar L. Minocycline prevents morphine-induced apoptosis in rat cerebral cortex and lumbar spinal cord: a possible mechanism for attenuating morphine tolerance. Neurotox Res 2011;19:649–659.
   PubMed Web of Science ®Google Scholar
• Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004;279: 19948–19954.
   PubMed Web of Science ®Google Scholar
• Keilhoff G, Schild L, Fansa H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration. Exp Neurol 2008;212:189–200.
   PubMed Web of Science ®Google Scholar
• Castanares M, Vera Y, Erkkila K, Kyttanen S, Lue Y, Dunkel L, . Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis. Biochem Biophys Res Commun 2005;337:663–669.
   PubMed Web of Science ®Google Scholar
• Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, . Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182–2190.
   PubMed Web of Science ®Google Scholar
• Linardic CM, Hannun YA. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J Biol Chem 1994;269:23530–23537.
   PubMed Web of Science ®Google Scholar
• Tang CM, Hwang CS, Chen SD, Yang DI. Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: Roles of Bcl-2 and thioredoxin. Free Radic Biol Med 2011;50:710–721.
   PubMed Web of Science ®Google Scholar
• Mishra MK, Ghosh D, Duseja R, Basu A. Antioxidant potential of Minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 2009; 54:464–470.
   PubMed Web of Science ®Google Scholar
• Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 2004;27:314–318.
   PubMed Web of Science ®Google Scholar
• Schildknecht S, Pape R, Muller N, Robotta M, Marquardt A, Burkle A, . Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 2011;286:4991–5002.
   PubMed Web of Science ®Google Scholar